Humacyte
HUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Employees: 220
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
196% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 25
15% more capital invested
Capital invested by funds: $104M [Q1] → $119M (+$15.3M) [Q2]
8% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $3.21M
2.85% less ownership
Funds ownership: 39.58% [Q1] → 36.73% (-2.85%) [Q2]
7% less funds holding
Funds holding: 167 [Q1] → 156 (-11) [Q2]
18% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 38
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Barclays
Matt Miksic
|
$3.5
|
Overweight
Initiated
|
27 Aug 2025 |
|
TD Cowen
Joshua Jennings
|
$3.5
|
Buy
Maintained
|
12 Aug 2025 |
|
HC Wainwright & Co.
Swayampakula Ramakanth
|
$3
|
Buy
Maintained
|
12 Aug 2025 |
|
D. Boral Capital
Jason Kolbert
|
$25
|
Buy
Maintained
|
11 Aug 2025 |
Financial journalist opinion
